Paul OConnell
Overview
Explore the profile of Paul OConnell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
359
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
OConnell P, Alsaffar M
J Clin Psychopharmacol
. 2024 Nov;
45(1):55-57.
PMID: 39527675
No abstract available.
2.
Canaud G, Lopez Gutierrez J, Irvine A, Vabres P, Hansford J, Ankrah N, et al.
Genet Med
. 2023 Aug;
25(12):100969.
PMID: 37634128
Purpose: PIK3CA-related overgrowth spectrum (PROS) encompasses several rare conditions resulting from activating variants in PIK3CA. Alpelisib, a PI3Kα-selective inhibitor, targets the underlying etiology of PROS, offering a novel therapeutic approach...
3.
OConnell P, Ridolfi A, Fretault N
J Biopharm Stat
. 2023 Jan;
33(6):812-819.
PMID: 36710386
Rare disorders impact millions of children worldwide, and developing new medicines in this setting is associated with multiple challenges. In this paper, we share a successful story of how real-world...
4.
Conway R, Nikiphorou E, Demetriou C, Low C, Leamy K, Ryan J, et al.
Ir J Med Sci
. 2023 Jan;
192(5):2495-2500.
PMID: 36622628
Background: Poor COVID-19 outcomes occur with higher frequency in people with rheumatic and musculoskeletal diseases (RMD). Better understanding of the factors involved is crucial to informing patients and clinicians regarding...
5.
Fleseriu M, Biller B, Bertherat J, Young J, Hatipoglu B, Arnaldi G, et al.
Pituitary
. 2022 Oct;
25(6):959-970.
PMID: 36219274
Background: Many patients with Cushing's disease (CD) require long-term medical therapy to control their hypercortisolism. In the core phase of a Phase II study (LINC 2; NCT01331239), osilodrostat normalized mean...
6.
Conway R, Nikiphorou E, Demetriou C, Low C, Leamy K, Ryan J, et al.
Rheumatology (Oxford)
. 2022 Mar;
61(SI2):SI151-SI156.
PMID: 35258593
Objectives: Although evidence is accumulating globally, data on outcomes in rheumatic disease and COVID-19 in Ireland are limited. We used data from the COVID-19 Global Rheumatology Alliance (C19-GRA) to describe...
7.
Conway R, Nikiphorou E, Demetriou C, Low C, Leamy K, Ryan J, et al.
Rheumatol Adv Pract
. 2021 Oct;
5(2):rkab031.
PMID: 34622123
Objectives: Given the limited data regarding the risk of hospitalization in patients with rheumatic disease and coronavirus disease 2019 (COVID-19) in Ireland, we used the COVID-19 Global Rheumatology Alliance (GRA)...
8.
Groarke P, Jagernauth S, Peters S, Manzanero S, OConnell P, Cowderoy G, et al.
ANZ J Surg
. 2021 Aug;
91(10):2145-2152.
PMID: 34435426
Background: Advances in shoulder magnetic resonance imaging (MRI) and arthrography (MRA) have revolutionised musculoskeletal diagnosis and surgical planning. Despite this, the overall accuracy of MRI, with or without intra-articular contrast,...
9.
Kennedy H, Mullaney R, McKenna P, Thompson J, Timmons D, Gill P, et al.
BMC Psychiatry
. 2020 Oct;
20(1):515.
PMID: 33097036
Background: Prevention of violence due to severe mental disorders in psychiatric hospitals may require intrusive, restrictive and coercive therapeutic practices. Research concerning appropriate use of such interventions is limited by...
10.
Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A, et al.
Lancet Diabetes Endocrinol
. 2020 Jul;
8(9):748-761.
PMID: 32730798
Background: Cushing's disease is a rare endocrine disorder characterised by cortisol overproduction with severe complications. Therapies for cortisol reduction are often necessary. Here we report the outcomes from the pivotal...